Transdermal Skin Patches Market Size, Share & Trends Analysis Report By Type (Multi-layer Drug-in-Adhesive), By Application (Pain Relief), By Distribution Channel (Hospital Pharmacies), By Region, And Segment Forecasts, 2025 - 2030
Description
Transdermal Skin Patches Market Summary
The global transdermal skin patches market size was valued at USD 6.20 billion in 2024 and is projected to reach USD 9.55 billion by 2030, growing at a CAGR of 7.6% from 2025 to 2030. The market is increasing due to the growing incidence of chronic diseases such as cardiovascular disease, diabetes, chronic pain, etc., the enhanced preference of consumers for less-invasive treatment options, an aging population worldwide, and the technological advancement in transdermal drug delivery methods.
Transdermal patches offer a non-invasive and convenient approach to managing drugs through oral and injectable formulations; therefore, patients are more likely to take their medications as prescribed and experience lower gastrointestinal side effects than oral medications. Due to their ease of use and consistent drug-release rates over long periods, transdermal patches are especially appealing in chronic disease state management.
The industry is experiencing notable growth because of the rise of chronic diseases across the globe. In February 2024, the Centers for Disease Control and Prevention (CDC) estimates there are 129 million people in the United States with at least one key chronic disease, such as cancer, heart disease, obesity, diabetes, and hypertension. The most common treatment for chronic pain is to have the patient take pain relief medication daily, which is not only tedious, but oral or injectable forms often have bothersome side effects and burdensome frequency of administration. Transdermal patches can show efficacy in these scenarios as they improve adherence to medication therapy through regulated medication delivery over a longer period. For example, fentanyl transdermal patches have been approved for chronic pain management and will continuously release fentanyl over 72 hours, providing low-dose relief and reducing the frequency of administration.
Innovations like microneedles, iontophoresis, and permeation enhancers have broadened the transdermal drug delivery landscape, creating new possibilities for administering large molecules and biologics. Microneedle patches generate tiny channels to the skin to enhance the delivery of large-molecule drugs that are too large to administer transdermally. For instance, a microneedle patch containing insulin allows for a pain-free way of taking insulin rather than daily needles, which may optimize control of glycemic levels. Iontophoresis is a newer, innovative delivery strategy that utilizes a small electric charge to help push drugs through the skin.
Global Transdermal Skin Patches Market Report Segmentation
This report forecasts revenue growth at the global, regional, and country levels and analyzes the latest trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global transdermal skin patches market report by type, application, distribution channel, and region:
The global transdermal skin patches market size was valued at USD 6.20 billion in 2024 and is projected to reach USD 9.55 billion by 2030, growing at a CAGR of 7.6% from 2025 to 2030. The market is increasing due to the growing incidence of chronic diseases such as cardiovascular disease, diabetes, chronic pain, etc., the enhanced preference of consumers for less-invasive treatment options, an aging population worldwide, and the technological advancement in transdermal drug delivery methods.
Transdermal patches offer a non-invasive and convenient approach to managing drugs through oral and injectable formulations; therefore, patients are more likely to take their medications as prescribed and experience lower gastrointestinal side effects than oral medications. Due to their ease of use and consistent drug-release rates over long periods, transdermal patches are especially appealing in chronic disease state management.
The industry is experiencing notable growth because of the rise of chronic diseases across the globe. In February 2024, the Centers for Disease Control and Prevention (CDC) estimates there are 129 million people in the United States with at least one key chronic disease, such as cancer, heart disease, obesity, diabetes, and hypertension. The most common treatment for chronic pain is to have the patient take pain relief medication daily, which is not only tedious, but oral or injectable forms often have bothersome side effects and burdensome frequency of administration. Transdermal patches can show efficacy in these scenarios as they improve adherence to medication therapy through regulated medication delivery over a longer period. For example, fentanyl transdermal patches have been approved for chronic pain management and will continuously release fentanyl over 72 hours, providing low-dose relief and reducing the frequency of administration.
Innovations like microneedles, iontophoresis, and permeation enhancers have broadened the transdermal drug delivery landscape, creating new possibilities for administering large molecules and biologics. Microneedle patches generate tiny channels to the skin to enhance the delivery of large-molecule drugs that are too large to administer transdermally. For instance, a microneedle patch containing insulin allows for a pain-free way of taking insulin rather than daily needles, which may optimize control of glycemic levels. Iontophoresis is a newer, innovative delivery strategy that utilizes a small electric charge to help push drugs through the skin.
Global Transdermal Skin Patches Market Report Segmentation
This report forecasts revenue growth at the global, regional, and country levels and analyzes the latest trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global transdermal skin patches market report by type, application, distribution channel, and region:
- Type Outlook (Revenue, USD Unit, 2018 - 2030)
- Single-layer Drug-in-Adhesive
- Multi-layer Drug-in-Adhesive
- Matrix
- Other Types
- Application Outlook (Revenue, USD Billion, 2018 - 2030)
- Pain Relief
- Smoking Reduction and Cessation Aid
- Cardiovascular Disorders
- Neurological Disorders
- Hormonal Therapy
- Other Applications
- Distribution Channel Outlook (Revenue, USD Billion, 2018 - 2030)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Outlook (Revenue, USD Billion, 2018 - 2030)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- South Korea
- Australia
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
170 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Type
- 1.2.2. Application
- 1.2.3. Distribution Channel
- 1.2.4. Regional scope
- 1.2.5. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR’s internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.4.5.1. Data for primary interviews in North America
- 1.4.5.2. Data for primary interviews in Europe
- 1.4.5.3. Data for primary interviews in the Asia Pacific
- 1.4.5.4. Data for primary interviews in Latin America
- 1.4.5.5. Data for Primary interviews in MEA
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Type Outlook
- 2.2.2. Application Outlook
- 2.2.3. Distribution Channel Outlook
- 2.2.4. Regional outlook
- 2.3. Competitive Insights
- Chapter 3. Transdermal Skin Patches Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Rising prevalence of chronic diseases
- 3.2.1.2. Increased consumer preference for minimally invasive treatment
- 3.2.1.3. Aging global population
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. Skin irritation and allergic reactions
- 3.2.2.2. Limited awareness
- 3.2.3. Industry Analysis - Porter’s
- 3.2.3.1. Bargaining power of the suppliers
- 3.2.3.2. Bargaining power of the buyers
- 3.2.3.3. Threats of substitution
- 3.2.3.4. Threats from new entrants
- 3.2.3.5. Competitive rivalry
- 3.2.4. PESTEL Analysis
- 3.2.4.1. Political landscape
- 3.2.4.2. Economic landscape
- 3.2.4.3. Social landscape
- 3.2.4.4. Technological landscape
- 3.2.4.5. Environmental landscape
- 3.2.4.6. Legal landscape
- Chapter 4. Transdermal Skin Patches Market: Type Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Transdermal Skin Patches Market: Type Movement Analysis, USD Billion, 2018 & 2030
- 4.3. Transdermal Skin Patches Market by Product Outlook (USD Million)
- 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 4.5. Single-layer Drug-in-Adhesive
- 4.5.1. Single-layer Drug-in-Adhesive Market Estimates And Forecasts, 2018 to 2030 (USD Billion)
- 4.6. Multi-layer Drug-in-Adhesive
- 4.6.1. Multi-layer Drug-in-Adhesive Market Estimates And Forecasts, 2018 to 2030 (USD Billion)
- 4.7. Matrix
- 4.7.1. Matrix Market Estimates And Forecasts, 2018 to 2030(USD Billion)
- 4.8. Other Types
- 4.8.1. Other Types Market Estimates And Forecasts, 2018 to 2030(USD Billion)
- Chapter 5. Transdermal Skin Patches Market: Application Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Transdermal Skin Patches Market: Application Movement Analysis
- 5.3. Transdermal Skin Patches Market by Function Outlook (USD Billion)
- 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 5.5. Pain Relief
- 5.5.1. Pain Relief Market Estimates And Forecasts, 2018 to 2030(USD Billion)
- 5.6. Smoking Reduction and Cessation Aid
- 5.6.1. Smoking Reduction Market Estimates And Forecasts, 2018 to 2030(USD Billion)
- 5.7. Cardiovascular Disorders
- 5.7.1. Cardiovascular Disorders Market Estimates And Forecasts, 2018 to 2030(USD Billion)
- 5.8. Neurological Disorders
- 5.8.1. Neurological Disorders Market Estimates And Forecasts, 2018 to 2030(USD Billion)
- 5.9. Hormonal Therapy
- 5.9.1. Hormonal Therapy Market Estimates And Forecasts, 2018 to 2030(USD Billion)
- 5.10. Other Applications
- 5.10.1. Other Applications Market Estimates And Forecasts, 2018 to 2030(USD Billion)
- Chapter 6. Transdermal Skin Patches Market: Distribution Channel Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Transdermal Skin Patches Market: Distribution Channel Movement Analysis
- 6.3. Transdermal Skin Patches Market: Distribution Channel Movement Analysis, USD Billion, 2018 & 2030
- 6.4. Hospital Pharmacies
- 6.4.1. Hospital Pharmacies Market Estimates And Forecasts, 2018 to 2030(USD Billion)
- 6.5. Retail Pharmacies
- 6.5.1. Retail Pharmacies Market Estimates And Forecasts, 2018 to 2030(USD Billion)
- 6.6. Online Pharmacies
- 6.6.1. Online Pharmacies Market Estimates And Forecasts, 2018 to 2030(USD Billion)
- Chapter 7. Transdermal Skin Patches Market: Regional Estimates & Trend Analysis
- 7.1. Regional Market Share Analysis, 2024 & 2030
- 7.2. Regional Market Dashboard
- 7.3. Global Regional Market Snapshot
- 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
- 7.5. North America
- 7.5.1. North America Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.2. U.S.
- 7.5.2.1. Key Country Dynamics
- 7.5.2.2. Competitive Scenario
- 7.5.2.3. Regulatory Framework
- 7.5.2.4. Reimbursement scenario
- 7.5.2.5. U.S. Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.3. Canada
- 7.5.3.1. Key Country Dynamics
- 7.5.3.2. Competitive Scenario
- 7.5.3.3. Regulatory Framework
- 7.5.3.4. Reimbursement scenario
- 7.5.3.5. Canada Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.4. Mexico
- 7.5.4.1. Key Country Dynamics
- 7.5.4.2. Competitive Scenario
- 7.5.4.3. Regulatory Framework
- 7.5.4.4. Reimbursement scenario
- 7.5.4.5. Mexico Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6. Europe
- 7.6.1. Europe Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.2. UK
- 7.6.2.1. Key Country Dynamics
- 7.6.2.2. Competitive Scenario
- 7.6.2.3. Regulatory Framework
- 7.6.2.4. Reimbursement scenario
- 7.6.2.5. UK Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.3. Germany
- 7.6.3.1. Key Country Dynamics
- 7.6.3.2. Competitive Scenario
- 7.6.3.3. Regulatory Framework
- 7.6.3.4. Reimbursement scenario
- 7.6.3.5. Germany Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.4. France
- 7.6.4.1. Key Country Dynamics
- 7.6.4.2. Competitive Scenario
- 7.6.4.3. Regulatory Framework
- 7.6.4.4. Reimbursement scenario
- 7.6.4.5. France Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.5. Italy
- 7.6.5.1. Key Country Dynamics
- 7.6.5.2. Competitive Scenario
- 7.6.5.3. Regulatory Framework
- 7.6.5.4. Reimbursement scenario
- 7.6.5.5. Italy Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.6. Spain
- 7.6.6.1. Key Country Dynamics
- 7.6.6.2. Competitive Scenario
- 7.6.6.3. Regulatory Framework
- 7.6.6.4. Reimbursement scenario
- 7.6.6.5. Spain Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.7. Denmark
- 7.6.7.1. Key Country Dynamics
- 7.6.7.2. Competitive Scenario
- 7.6.7.3. Regulatory Framework
- 7.6.7.4. Reimbursement scenario
- 7.6.7.5. Denmark Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.8. Sweden
- 7.6.8.1. Key Country Dynamics
- 7.6.8.2. Competitive Scenario
- 7.6.8.3. Regulatory Framework
- 7.6.8.4. Reimbursement scenario
- 7.6.8.5. Sweden Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.9. Norway
- 7.6.9.1. Key Country Dynamics
- 7.6.9.2. Competitive Scenario
- 7.6.9.3. Regulatory Framework
- 7.6.9.4. Reimbursement scenario
- 7.6.9.5. Norway Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7. Asia Pacific
- 7.7.1. Asia Pacific Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7.2. Japan
- 7.7.2.1. Key Country Dynamics
- 7.7.2.2. Competitive Scenario
- 7.7.2.3. Regulatory Framework
- 7.7.2.4. Reimbursement scenario
- 7.7.2.5. Japan Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7.3. China
- 7.7.3.1. Key Country Dynamics
- 7.7.3.2. Competitive Scenario
- 7.7.3.3. Regulatory Framework
- 7.7.3.4. Reimbursement scenario
- 7.7.3.5. China Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7.4. India
- 7.7.4.1. Key Country Dynamics
- 7.7.4.2. Competitive Scenario
- 7.7.4.3. Regulatory Framework
- 7.7.4.4. Reimbursement scenario
- 7.7.4.5. India Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7.5. South Korea
- 7.7.5.1. Key Country Dynamics
- 7.7.5.2. Competitive Scenario
- 7.7.5.3. Regulatory Framework
- 7.7.5.4. Reimbursement scenario
- 7.7.5.5. South Korea Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7.6. Australia
- 7.7.6.1. Key Country Dynamics
- 7.7.6.2. Competitive Scenario
- 7.7.6.3. Regulatory Framework
- 7.7.6.4. Reimbursement scenario
- 7.7.6.5. Australia Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7.7. Thailand
- 7.7.7.1. Key Country Dynamics
- 7.7.7.2. Competitive Scenario
- 7.7.7.3. Regulatory Framework
- 7.7.7.4. Reimbursement scenario
- 7.7.7.5. Thailand Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8. Latin America
- 7.8.1. Latin America Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8.2. Brazil
- 7.8.2.1. Key Country Dynamics
- 7.8.2.2. Competitive Scenario
- 7.8.2.3. Regulatory Framework
- 7.8.2.4. Reimbursement scenario
- 7.8.2.5. Brazil Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8.3. Argentina
- 7.8.3.1. Key Country Dynamics
- 7.8.3.2. Competitive Scenario
- 7.8.3.3. Regulatory Framework
- 7.8.3.4. Reimbursement scenario
- 7.8.3.5. Argentina Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.9. Middle East & Africa
- 7.9.1. Middle East & Africa Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.9.2. South Africa
- 7.9.2.1. Key Country Dynamics
- 7.9.2.2. Competitive Scenario
- 7.9.2.3. Regulatory Framework
- 7.9.2.4. Reimbursement scenario
- 7.9.2.5. South Africa Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.9.3. Saudi Arabia
- 7.9.3.1. Key Country Dynamics
- 7.9.3.2. Competitive Scenario
- 7.9.3.3. Regulatory Framework
- 7.9.3.4. Reimbursement scenario
- 7.9.3.5. Saudi Arabia Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.9.4. UAE
- 7.9.4.1. Key Country Dynamics
- 7.9.4.2. Competitive Scenario
- 7.9.4.3. Regulatory Framework
- 7.9.4.4. Reimbursement scenario
- 7.9.4.5. UAE Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.9.5. Kuwait
- 7.9.5.1. Key Country Dynamics
- 7.9.5.2. Competitive Scenario
- 7.9.5.3. Regulatory Framework
- 7.9.5.4. Reimbursement scenario
- 7.9.5.5. Kuwait Transdermal Skin Patches Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- Chapter 8. Competitive Landscape
- 8.1. Recent Developments & Impact Analysis, By Key Market Participants
- 8.2. Company/Competition Categorization
- 8.3. Vendor Landscape
- 8.3.1. Key company market share analysis, 2024
- 8.3.2. Teva Pharmaceutical Industries Ltd
- 8.3.2.1. Company overview
- 8.3.2.2. Financial performance
- 8.3.2.3. Type benchmarking
- 8.3.2.4. Strategic initiatives
- 8.3.3. Novartis AG
- 8.3.3.1. Company overview
- 8.3.3.2. Financial performance
- 8.3.3.3. Type benchmarking
- 8.3.3.4. Strategic initiatives
- 8.3.4. Teikoku Pharma USA Inc.
- 8.3.4.1. Company overview
- 8.3.4.2. Financial performance
- 8.3.4.3. Type benchmarking
- 8.3.4.4. Strategic initiatives
- 8.3.5. Viatris Inc.
- 8.3.5.1. Company overview
- 8.3.5.2. Financial performance
- 8.3.5.3. Type benchmarking
- 8.3.5.4. Strategic initiatives
- 8.3.6. Johnson & Johnson
- 8.3.6.1. Company overview
- 8.3.6.2. Financial performance
- 8.3.6.3. Type benchmarking
- 8.3.6.4. Strategic initiatives
- 8.3.7. Luye Pharma Group
- 8.3.7.1. Company overview
- 8.3.7.2. Financial performance
- 8.3.7.3. Type benchmarking
- 8.3.7.4. Strategic initiatives
- 8.3.8. Purdue Pharma Manufacturing LP
- 8.3.8.1. Company overview
- 8.3.8.2. Financial performance
- 8.3.8.3. Type benchmarking
- 8.3.8.4. Strategic initiatives
- 8.3.9. Henan Lingrui Pharmaceutical Ltd
- 8.3.9.1. Company overview
- 8.3.9.2. Financial performance
- 8.3.9.3. Type benchmarking
- 8.3.9.4. Strategic initiatives
- 8.3.10. Samyang Biopharmaceuticals Corp.
- 8.3.10.1. Company overview
- 8.3.10.2. Financial performance
- 8.3.10.3. Type benchmarking
- 8.3.10.4. Strategic initiatives
- 8.3.11. Hisamitsu Pharmaceutical Co, Inc.
- 8.3.11.1. Company overview
- 8.3.11.2. Financial performance
- 8.3.11.3. Type benchmarking
- 8.3.11.4. Strategic initiatives
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
